Adding temozolomide to radiotherapy improves survival in patients with glioblastoma
In short: A randomized trial of 573 patients with newly diagnosed glioblastoma found that combining radiotherapy with the drug temozolomide increased median survival to 14.6 months, compared to 12.1 months for radiotherapy alone. The study observed that this combination therapy also significantly improved the two-year survival rate from 10.4 percent to 26.5 percent.
Researchers compared radiotherapy alone against a regimen of radiotherapy plus continuous daily temozolomide, followed by six cycles of adjuvant temozolomide. While the addition of the drug provided a statistically significant survival benefit, the study noted that 7 percent of patients in the combination group experienced grade 3 or 4 hematologic toxic effects.
Why it matters: Combining temozolomide with radiotherapy offers a significant survival advantage for patients facing this aggressive brain tumor.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Stupp et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-adding-temozolomide-to-radiotherapy-improves-survival-in-pat.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
